Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · head-neck@1

SRR15069616

—

4c7d9402-33dc-5521-a451-254990257e7b

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.520
  • INTERFERON_GAMMA_RESPONSE+0.340
  • MYC_TARGETS_V2+0.330
  • ESTROGEN_RESPONSE_LATE+0.320
  • G2M_CHECKPOINT+0.310
  • E2F_TARGETS+0.290
  • ESTROGEN_RESPONSE_EARLY+0.290
  • MTORC1_SIGNALING+0.280
  • MYC_TARGETS_V1+0.250
  • OXIDATIVE_PHOSPHORYLATION+0.230

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
  • ANGIOGENESIS-0.340
  • KRAS_SIGNALING_UP-0.250
  • WNT_BETA_CATENIN_SIGNALING-0.250
  • MYOGENESIS-0.220
  • UV_RESPONSE_DN-0.220
  • APICAL_JUNCTION-0.180
  • ALLOGRAFT_REJECTION-0.170
  • COAGULATION-0.160
  • TNFA_SIGNALING_VIA_NFKB-0.140

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR15069615
head-neck@1
——0.811
2TCGA-A2-A0CW-01A-21R-A115-07
breast-umap@18
—B0.793
3SRR25617854
breast-umap@18
—C0.775
4SRR6013515
lung-landscapes@6
—cohortA40.775
5SRR8518193
breast-umap@18
—C0.766
6TCGA-AO-A03O-01A-11R-A00Z-07
breast-umap@18
—C0.765
7SRR25043614
head-neck@1
——0.764
8TCGA-A8-A08S-01A-11R-A034-07
breast-umap@18
—B0.760
9TCGA-66-2794-01A-01R-1201-07
lung-landscapes@6
—cohortSQ20.759
1081b828aa-cb06-4790-ba3e-efaa39f4eeef
colon-landscapes@1
——0.748

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 30 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.520Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.340Idelalisib— uncovered
MYC_TARGETS_V20.330Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.320Idelalisib— uncovered
G2M_CHECKPOINT0.310Inavolisib— uncovered
E2F_TARGETS0.290Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.290Inavolisib— uncovered
MTORC1_SIGNALING0.280Inavolisib— uncovered
MYC_TARGETS_V10.250Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.230Remibrutinib— uncovered
HEDGEHOG_SIGNALING0.200Inavolisib— uncovered
ANDROGEN_RESPONSE0.180Inavolisib— uncovered
FATTY_ACID_METABOLISM0.180Inavolisib— uncovered
MITOTIC_SPINDLE0.150Inavolisib— uncovered
PEROXISOME0.150Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.150Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.140Remibrutinib— uncovered
HEME_METABOLISM0.120Temsirolimus— uncovered
UV_RESPONSE_UP0.120Idelalisib— uncovered
GLYCOLYSIS0.110Inavolisib— uncovered